Which medication, when noted in a patient’s history, will diminish the effects of Warfarin (Coumadin)?

Choice A rationale
Furosemide (Lasix) is a diuretic often used in the treatment of pulmonary edema to help remove excess fluid from the body. While it’s important to monitor the patient’s fluid and electrolyte balance, it’s not typically necessary to question this medication.
Choice B rationale
Captopril (Capoten) is an ACE inhibitor used to treat conditions like heart failure and high blood pressure. It can be beneficial in managing pulmonary edema by reducing the workload on the heart. It’s not typically necessary to question this medication.
Choice C rationale
Digoxin (Lanoxin) is a medication used to treat heart failure and atrial fibrillation. It’s important to question this medication before administration because digoxin has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is small. Therefore, it’s crucial to ensure the patient’s digoxin levels are within the therapeutic range before administering more of the medication.
Choice D rationale
Carvedilol (Coreg) is a beta-blocker used to treat high blood pressure and heart failure. While it’s important to monitor the patient’s blood pressure and heart rate, it’s not typically necessary to question this medication.

Choice A rationale
Bleeding from the gums is a sign of excessive bleeding, which can be a side effect of thrombolytic therapy. Thrombolytic agents work by dissolving blood clots, but they can also interfere with the body’s normal clotting mechanism, leading to bleeding. If a patient experiences unusual or excessive bleeding, it may be necessary to stop the infusion of the thrombolytic agent.
Choice B rationale
An increase in blood pressure is not typically a reason to stop the infusion of a thrombolytic agent in a patient with an acute myocardial infarction. While blood pressure should be monitored closely during thrombolytic therapy, an increase in blood pressure is not a common side effect.
Choice C rationale
A nonsustained episode of ventricular tachycardia is not typically a reason to stop the infusion of a thrombolytic agent in a patient with an acute myocardial infarction. While arrhythmias can occur during a myocardial infarction, they are not a common side effect of thrombolytic therapy.
Choice D rationale
A decreased level of consciousness can be a sign of many serious conditions, including bleeding in the brain. However, it is not typically a reason to stop the infusion of a thrombolytic agent unless it is accompanied by other signs of excessive bleeding.